Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes

Atherosclerosis

Volumn 214, Issue 2, 2011, Pages 462-467

  Lopes Virella, Maria F ^a,b   Baker, Nathaniel L ^a   Hunt, Kelly J ^a   Lachin, John ^c   Nathan, David ^d   Virella, G ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Coronary artery calcification; Coronary artery disease; Immune complexes; Immunology of atherosclerosis; Macrovascular disease; Oxidized LDL; Oxidized LDL antibodies; Type 1 diabetes; Vascular inflammation

Indexed keywords

HEMOGLOBIN A1C; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADOLESCENT; ADULT; ANTIGEN ANTIBODY COMPLEX; ARTERY CALCIFICATION; ARTICLE; BLOOD PRESSURE; CIGARETTE SMOKING; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY CALCIFICATION; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RETINOPATHY; RISK FACTOR; SCORING SYSTEM;

ADOLESCENT; ADULT; ANTIGEN-ANTIBODY COMPLEX; CALCINOSIS; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNITY, HUMORAL; INSULIN; LIPOPROTEINS, LDL; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; UNITED STATES; YOUNG ADULT;

EID: 79151476184     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.11.012     Document Type: Article

References (31)

1. Lundberg A.M., Hansson G.K. Innate immune signals in atherosclerosis. Clin Immunol 2010, 134:5-24.
2. Andersson J., Libby P., Hansson G.K. Adaptive immunity and atherosclerosis. Clin Immunol 2010, 134:33-46.
3. Lopes-Virella M.F., Virella G. Clinical significance of the humoral immune response to modified LDL. Clin Immunol 2010, 134:55-65.
4. Amir S., Binder C.J. Experimental immunotherapeutic approaches for atherosclerosis. Clin Immunol 2010, 134:66-79.
5. Saad A.F., Virella G., Chassereau C., et al. OxLDL immune complexes activate complement and induce cytokine production by MonoMac 6 cells and human macrophages. J Lipid Res 2006, 47:1975-1983.
6. Virella G., Atchley D.H., Koskinen S., et al. Pro-atherogenic and pro-inflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. Clin Immunol 2002, 105:81-92.
7. Mironova M., Virella G., Virella-Lowell I., et al. Anti-modified LDL antibodies and LDL-containing immune complexes in IDDM patients and healthy controls. Clin Immunol Immunopath 1997, 85:73-82.
8. Lopes-Virella M.F., Virella G., Orchard T.J., et al. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin Immunol 1999, 90:165-172.
9. Lopes-Virella M.F., McHenry M.B., Lipsitz S., et al. Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes. Atherosclerosis 2007, 190:359-369.
10. Orchard T.J., Virella G., Forrest K.Y., et al. Antibodies to oxidized LDL predict coronary artery disease in type 1 diabetes: a nested case-control study from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 1999, 48:1454-1458.
11. Yishak A.A., Costacou T., Virella G., et al. Novel predictors of overt nephropathy in subjects with type 1 diabetes. A nested case control study from the Pittsburgh Epidemiology of Diabetes Complications cohort. Nephrol Dial Transplant 2006, 21:93-100.
12. Griffith R.L., Virella G.T., Stevenson H.C., et al. Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes. A possible mechanism of foam cell formation. J Exp Med 1988, 168:1041-1059.
13. Lopes-Virella M.F., Binzafar N., Rackley S., et al. The uptake of LDL-IC by human macrophages: predominant involvement of the Fc gamma RI receptor. Atherosclerosis 1997, 135:161-170.
14. Yla-Herttuala S., Palinski W., Rosenfeld M.E., et al. Lipoproteins in normal and atherosclerotic aorta. Eur Heart J 1990, 11:88-89.
15. Yla-Herttuala S., Palinski W., Butler S., et al. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 1994, 14:32-40.
16. Atchley D.H., Lopes-Virella M.F., Zheng D., et al. Oxidized LDL-Anti-Oxidized LDL immune complexes and diabetic nephropathy. Diabetologia 2002, 45:1562-1571.
17. Virella G., Derrick M.B., Pate V., et al. Development of capture assays for different modifications of human low-density lipoprotein. Clin Diagn Lab Immunol 2005, 12:68-75.
18. Cleary P.A., Orchard T.J., Genuth S., et al. The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes 2006, 55:3556-3565.
19. The Diabetes Control Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986.
20. Epidemiology of Diabetes Interventions Complications (EDIC) Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial Cohort. Diabetes Care 1999, 22:99-111.
21. Hodis H.N., Mack W.J., LaBree L., et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998, 128:262-269.
22. Virella G., Thorpe S., Alderson N.L., et al. Definition of the immunogenic forms of modified human LDL recognized by human autoantibodies and by rabbit hyperimmune antibodies. J Lipid Res 2004, 45:1859-1867.
23. Feasibility of centralized measurements of glycated hemoglobin in the Diabetes Control and Complications Trial: a multicenter study. The DCCT Research Group. Clin Chem 1987, 33:2267-2271.
24. Early Treatment Diabetic Retinopathy Study Research Group Fundus photographic risk factors for progression of diabetic retinopathy: ETDRS report number 12. Ophthalmology 1991, 98(Suppl.):823-833.
25. Greenland P., Bonow R.O., Brundage B.H., et al. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography) developed in collaboration with the Society of Atherosclerosis Imaging and Prevention and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol 2007, 49:378-402.
26. Hoffmann U., Brady T.J., Muller J. Cardiology patient page. Use of new imaging techniques to screen for coronary artery disease. Circulation 2003, 108:e50-e53.
27. Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004, 159:702-706.
28. Tobin J. Estimation of relationships for limited dependent variables. Econometrica 1958, 26:24-36.
29. Reilly M.P., Wolfe M.L., Localio A.R., et al. Coronary artery calcification and cardiovascular risk factors: impact of the analytic approach. Atherosclerosis 2004, 173:69-78.
30. Klein RL, Carter RE, Jenkins AJ, et al. LDL-containing immune complexes in the DCCT/EDIC cohort: associations with lipoprotein subclasses. J Diabetes Complications 2010 Jun 2. [Epub ahead of print], doi:10.1016/j.jdiacomp.2010.03.001.
31. Lopes-Virella M.F., Hunt K.J., Baker N.L., et al. The levels of oxidized LDL and AGE-LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes. Diabetes 2011, 60:1-8.